
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Author(s) -
R.J. Landovitz,
S. Li,
B. Grinsztejn,
H. Dawood,
A.Y. Liu,
M. Magnus,
M.C. Hosseinipour,
R. Panchia,
L. Cottle,
G. Chau,
P. Richardson,
M.A. Marzinke,
C.W. Hendrix,
S.H. Eshleman,
Y. Zhang,
E. Tolley,
J. Sugarman,
R. Kofron,
A. Adeyeye,
D. Burns,
A.R. Rinehart,
D. Margolis,
W.R. Spreen,
Myron S. Cohen,
M. McCauley,
Joe Eron
Publication year - 2018
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/mnq7-rm09
Subject(s) - tolerability , pharmacokinetics , human immunodeficiency virus (hiv) , medicine , pharmacology , randomized controlled trial , adverse effect , virology